Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy
Abstract
Rec ently, the number of publications concerning the use of liquid biopsy and, in particular, circulated tumor DNA (ctDNA) as well as the role of KRAS, BRAF, PIK3CA, and TP53 mutations for the diagnosis of early relapse in patients with colorectal cancer (CRC) has increased. However, it is necessary to accumulate a larger pool of data confirming its effectiveness and reliabi l ity for further implementation in clinical practice. The aim of this study was to determine the prevalence and impact of KRAS, BRAF, PIK3CA, and TP53 mutations on the survival of patients with stages I–III (CRC) using digital polymerase chain reaction (dPCR) and to evaluate the effectiveness of liquid biopsy in detecting ctDNA and predicting disease recurrence. 138 patients, scheduled for radical surgery for stage I–III CRC, were included in the study. DNA was extracted from tumor tissue samples and 3 plasma samples (obtained within 24 hours prior to surgery, 24 ± 1 hour and 90 ± 5 days after surgery) and then analyzed using dPCR for KRAS, BRAF, PIK3CA, and TP53 mutations. The dPCR was carried out using the QuantStudio 3D Digital PCR System (Applied Biosystems by ThermoFisher Scientific, USA) with the appropriate TaqMan Liquid Biopsy dPCR Assays (ThermoFisher Scientific, USA) (KRAS_512 (p.G12D), BRAF_476 (p.V600E), PIK3CA_775 (p.H1047R), and TP53_10662 (p.R248Q)). The studied mutations were found in 34 (24.6%) out of 138 tumor tissue samples. The prevalence of mutations in the study cohort was: KRAS – 9.4%, BRAF – 8.7%, PIK3CA – 3.6%, TP53 – 4.4%. The presence of at least one of the studied mutations significantly affected recurrence-free survival ( RFS ). The sensitivity of liquid biopsy for detecting ctDNA was 79.4%, and specificity was 100.0%. The recurrence rate was 59.3% for ctDNA-positive patients and 9.9% for ctDNA-negative patients. Liquid biopsy detected disease recurrence 2.14 months earlier than CT and colonoscopy. Ultimately, our findings support the role of liquid biopsy, particularly ctDNA, in advancing personalized treatment strategies for CRC.References
Balboa-Barreiro, V., Pértega-Díaz, S., García-Rodríguez, T., González-Martín, C., Pardeiro-Pértega, R., Yáñez-González-Dopeso, L., & Seoane-Pillado, T. (2024). Colorectal cancer recurrence and its impact on survival after curative surgery: An analysis based on multistate models. Digestive and Liver Disease, 56(7), 1229–1236.
Bittla, P., Kaur, S., Sojitra, V., Zahra, A., Hutchinson, J., Folawemi, O., & Khan, S. (2023). Exploring circulating tumor DNA (CtDNA) and its role in early detection of cancer: A systematic review. Cureus, 15(9), e45784.
Boute, T. C., Swartjes, H., Greuter, M. J. E., Elferink, M. A. G., van Eekelen, R., Vink, G. R., de Wilt, J. H. W., & Coupé, V. M. H. (2024). Cumulative incidence, risk factors, and overall survival of disease recurrence after curative resection of stage II–III colorectal cancer: A population-based study. Cancer Research Communications, 4(2), 607–616.
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020). Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 1(3), 276–290.
Chen, G., Peng, J., Xiao, Q., Wu, H. X., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., Wang, D., Shao, Y., Bao, H., Pan, Z., Ding, K. F., Cai, S., Wang, F., & Xu, R. H. (2021). Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology, 14(1), 80.
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., Li, Q., Zhang, H., & Di, C. (2022). Mutant p53 in cancer: From molecular mechanism to therapeutic modulation. Cell Death and Disease, 13(11), 974.
Chung, D. C., Gray, D. M. 2nd, Singh, H., Issaka, R. B., Raymond, V. M., Eagle, C., Hu, S., Chudova, D. I., Talasaz, A., Greenson, J. K., Sinicrope, F. A., Gupta, S., & Grady, W. M. (2024). A cell-free DNA blood-based test for colorectal cancer screening. The New England Journal of Medicine, 390(11), 973–983.
Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022). BRAF-mutated advanced colorectal cancer: A rapidly changing therapeutic landscape. Journal of Clinical Oncology, 40, 2706–2715.
Feroz, W., & Sheikh, A. M. A. (2020). Exploring the multiple roles of guardian of the genome: P53. Egyptian Journal of Medical Human Genetics, 21, 49.
Hruzyeva, T. S., Lytvynova, L. O., Grechishkina, N. V., Zamkevych, V. B., Donik, O. M., & Inshakova, H. V. (2018). Social medicine, public health. National Medical University named after O. O. Bohomolets, Kyiv.
Khakoo, S., Carter, P. D., Brown, G., Valeri, N., Picchia, S., Bali, M. A., Shaikh, R., Jones, T., Begum, R., Rana, I., Wotherspoon, A., Terlizzo, M., von Loga, K., Kalaitzaki, E., Saffery, C., Watkins, D., Tait, D., Chau, I., Starling, N., Hubank, M., & Cunningham, D. (2020). MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clinical Cancer Research, 26(1), 183–192.
Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., Hamilton, P., Xie, T., Yaeger, R., & Tabernero, J. (2024). Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nature Medicine, 30(11), 3261–3271.
Li, Q. H., Wang, Y. Z., Tu, J., Liu, C. W., Yuan, Y. J., Lin, R., He, W. L., Cai, S. R., He, Y. L., & Ye, J. N. (2020). Anti-EGFR therapy in metastatic colorectal cancer: Mechanisms and potential regimens of drug resistance. Gastroenterology Report, 8(3), 179–191.
Maji, L., Teli, G., Raghavendra, N. M., Sengupta, S., Pal, R., Ghara, A., & Matada, G. S. P. (2023). An updated literature on BRAF inhibitors (2018–2023). Molecular Diversity, 28(4), 2689–2730.
Mas, L., Bachet, J. B., Taly, V., Bouché, O., Taieb, J., Cohen, R., Meurisse, A., Normand, C., Gornet, J. M., Artru, P., Louafi, S., Thirot-Bidault, A., Baumgaertner, I., Coriat, R., Tougeron, D., Lecomte, T., Mary, F., Aparicio, T., Marthey, L., Blons, H., … Laurent-Puig, P. (2019). BRAF mutation status in circulating tumor DNA from patients with metastatic colorectal cancer: Extended mutation analysis from the AGEO RASANC study. Cancers, 11(7), 998.
Moskalenko, Y. V., Vynnychenko, O. I., Sulaieva, O. M., & Moskalenko, R. A. (2023). The role of next-generation sequencing in lung cancer diagnosis. Eastern Ukrainian Medical Journal, 11(3), 214–223.
Najafi, S., Majidpoor, J., & Mortezaee, K. (2024). Liquid biopsy in colorectal cancer. Clinica Chimica Acta, 553, 117674.
Nakamura, Y., Watanabe, J., Akazawa, N., Hirata, K., Kataoka, K., Yokota, M., Kato, K., Kotaka, M., Kagawa, Y., Yeh, K. H., Mishima, S., Yukami, H., Ando, K., Miyo, M., Misumi, T., Yamazaki, K., Ebi, H., Okita, K., Hamabe, A., Sokuoka, H., & Oki, E. (2024). ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nature Medicine, 30(11), 3272–3283.
Nikanjam, M., Kato, S., & Kurzrock, R. (2022). Liquid biopsy: Current technology and clinical applications. Journal of Hematology and Oncology, 15, 131.
Ogunwobi, O. O., Mahmood, F., & Akingboye, A. (2020). Biomarkers in colorectal cancer: Current research and future prospects. International Journal of Molecular Sciences, 21(15), 5311.
Oh, H. H., & Joo, Y. E. (2020). Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intestinal Research, 18(2), 168–183.
Scarlotta, M., Simsek, C., & Kim, A. K. (2019). Liquid biopsy in solid malignancy. Genetic Testing and Molecular Biomarkers, 23(4), 284–296.
Sclafani, F., Wilson, S. H., Cunningham, D., Gonzalez De Castro, D., Kalaitzaki, E., Begum, R., Wotherspoon, A., Capdevila, J., Glimelius, B., Roselló, S., Thomas, J., Tait, D., Brown, G., Oates, J., & Chau, I. (2020). Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 146(1), 94–102.
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020). Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes, 11(11), 1342.
Suzuki, T., Suzuki, T., Yoshimura, Y., Yahata, M., Yew, P. Y., Nakamura, T., Nakamura, Y., Park, J. H., & Matsuo, R. (2020). Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers. Oncotarget, 11(34), 3198–3207.
Tao, X. Y., Li, Q. Q., & Zeng, Y. (2024). Clinical application of liquid biopsy in colorectal cancer: Detection, prediction, and treatment monitoring. Molecular Cancer, 23(1), 145.
Testa, U., Castelli, G., & Pelosi, E. (2020). Genetic alterations of metastatic colorectal cancer. Biomedicines, 8, 414.
Tsai, T. J., Syu, K. J., Huang, X. Y., Liu, Y. S., Chen, C. W., Wu, Y. H., Lin, C. M., & Chang, Y. Y. (2024). Identifying timing and risk factors for early recurrence of resectable rectal cancer: A single center retrospective study. World Journal of Gastrointestinal Surgery, 16(9), 2842–2852.
Uprety, N., & Adjei, A. A. (2020). KRAS: From undruggable to a druggable cancer target. Cancer Treatment Reviews, 89, 102070.
Vacante, M., Ciuni, R., Basile, F., & Biondi, A. (2020). The liquid biopsy in the management of colorectal cancer: An overview. Biomedicines, 8(9), 308.
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021). PI3K inhibitors are finally coming of age. Nature reviews. Drug Discovery, 20(10), 741–769.
Voutsadakis, I. A. (2021). The landscape of PIK3CA mutations in colorectal cancer. Clinical Colorectal Cancer, 20(3), 201–215.
Zheng, Z., Wang, X., Huang, Y., Lu, X., Huang, Z., & Chi, P. (2020). Defining and predicting early recurrence in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. European Journal of Surgical Oncology, 46(11), 2057–2063.
Zhou, H., Zhu, L., Song, J., Wang, G., Li, P., Li, W., Luo, P., Sun, X., Wu, J., Liu, Y., Zhu, S., & Zhang, Y. (2022). Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Molecular Cancer, 21(1), 86.
Zhou, J., Ji, Q., & Li, Q. (2021). Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies. Journal of Experimental and Clinical Cancer Research, 40, 328.
Zhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., & Liu, P. (2021). Multi gene mutation signatures in colorectal cancer patients: Predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer, 21(1), 380.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
